Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage

Cardiovascular Toxicology

Volumn 2, Issue 2, 2002, Pages 111-118

  Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

ADR 925; Antioxidant; Calcein; Cardiotoxicity; Dexrazoxane; Hypoxia reoxygenation; Iron; Myocyte; Oxygen radical

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; LACTATE DEHYDROGENASE; RAZOXANE; CALCEIN; CARDIOVASCULAR AGENT; DRUG DERIVATIVE; ETHYLENEDIAMINE DERIVATIVE; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; GLYCINE;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL INCLUSION; CONTROLLED STUDY; ENZYME RELEASE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; HEART PROTECTION; IRON CHELATION; IRON KINETICS; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STROKE; TISSUE INJURY; ANIMAL; ANOXIA; BIOLOGICAL MODEL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; EXTRACORPOREAL OXYGENATION; ION TRANSPORT; METABOLISM; SPRAGUE DAWLEY RAT; TIME; TREATMENT FAILURE;

ANIMALIA; STAPHYLOCOCCUS PHAGE 187;

ANIMALS; ANOXIA; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLENEDIAMINES; EXTRACORPOREAL MEMBRANE OXYGENATION; FLUORESCEINS; FLUORESCENT DYES; GLYCINE; ION TRANSPORT; L-LACTATE DEHYDROGENASE; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE; TIME FACTORS; TREATMENT FAILURE;

EID: 0036363028     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:2:2:111     Document Type: Article

References (35)

1. Flaherty, J.T. and Zweier, J.L. (1991). Role of oxygen radicals in myocardial reperfusion injury: experimental and clinical evidence. Klin. Wochenschr. 69:1061-1065.
2. Horwitz, L.D. and Rosenthal, E.A. (1999). Iron-mediated cardiovascular injury. Vasc. Med. 4:93-99.
3. Reddy, B.R., Kloner, R.A., and Przyklenk, K. (1989). Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Radical Biol. Med. 7:45-52.
4. Hasinoff, B.B., Hellmann, K., Herman, E.H., and Ferrans, V.J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5:1-28.
5. Hasinoff, B.B. (1998). Chemistry of dexrazoxane and analogues. Semin. Oncol. 25(Suppl. 10):3-9.
6. Meyers, C.E. (1998). The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 25(Suppl. 10): 10-14.
7. Malisza, K.L. and Hasinoff, B.B. (1995). Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch. Biochem. Biophys. 321:51-60.
8. Halliwell, B. and Gutteridge, J.M.C. (1989). Free Radicals in Biology and Medicine, Clarendon, Oxford.
9. Hasinoff, B.B. (1990). The hydrolysis-activation of the doxorubicin cardioprotective agent ICRF-187 ((+)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane). Drug Metab. Dispos. 18:344-349.
10. Hasinoff, B.B. (1994). Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 83:64-67.
11. Hasinoff, B.B. (1994). An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)- 1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int. J. Pharm. 107:67-76.
12. Buss, J.L. and Hasinoff, B.B. (1993). The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95.
13. Diop, N.K., Vitellaro, L.K., Arnold, P., Shang, M., and Marusak, R.A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem. 78:209-216.
14. Huang, Z.-X., May, P.M., Quinlan, K.M., Williams, D.R., and Creighton, A.M. (1982). Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12:536-542.
15. Dawson, K.M. (1975). Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 24:2249-2253.
16. Rodriguez, R., Gerson, R., and Santiago-Mejia, J. (2000). Dexrazoxane-induced reduction in mortality in mice subjected to severe forebrain ischemia. Drug Dev. Res. 51: 149-152.
17. Herman, E.H., Hasinoff, B.B., Zhang, J., Raley, L.G., Zhang, T.-M., Fukada, Y., et al. (1995). Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 98:163-175.
18. Flandina, C., Sanguedolce, R., Rausa, L., and D'Alessandro, N. (1990). Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res. Commun. Chem. Pathol. Pharmacol. 70:259-272.
19. El-Hage, A.N., Herman, E.H., and Ferrans, V.J. (1983). Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminophen-induced hepatotoxicity in Syrian golden hamsters. Toxicology 28:295-303.
20. El-Hage, A., Herman, E.H., Yang, G.C., Crouch, R.K., and Ferrans, V.J. (1986). Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice. Res. Commun. Chem. Pathol. Pharmacol. 52:341-360.
21. Fukuda, Y., Herman, E.H., and Ferrans, V.J. (1992). Effect of ICRF-187 on the pulmonary damage induced by hyperoxia in the rat. Toxicology 74:185-202.
22. Elmadhoun, B.M., Wang, G.Q., Kirshenbaum, L.A., and Burczynski, F.J. (2001). Palmitate uptake by neonatal rat myocytes and hepatocytes. Role of extracellular protein. Eur. J. Biochem. 268:3145-3153.
23. Ek, B., Hallberg, C., Sjogren; K.-G., and Hjalmarson, A. (1994). Reoxygenation-induced cell damage of isolated neonatal rat ventricular myocytes can be reduced by chain-breaking antioxidants. Free Radical Biol. Med. 16:117-121.
24. Zanninelli, G., Glickstein, H., Breuer, W., Milgram, P., Brissot, P., Hider, R.C., et al. (1997). Chelation and mobilization of cellular iron by different classes of chelators. Mol. Pharmacol. 51:842-852.
25. Cabantchik, Z.I., Glickstein, H., Milgram, P., and Breuer, W. (1996). A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Anal. Biochem. 233:221-227.
26. 2 injury in adult cardiomyocytes. Cardiovasc. Res. 47:529-536.
27. Hershko, C., Link, G., Tzahor, M., Kaltwasser, J.P., Athias, P., Grynberg, A., et al. (1993). Anthracycline cytoxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J. Lab. Clin. Med. 122:245-251.
28. Herman, E.H., El-Hage, A.N., Creighton, A.M., Witiak, D.T., and Ferrans, V.J. (1985). Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in syrian golden hamsters. Res. Commun. Chem. Pathol. Pharmacol. 48:39-55.
29. Buss, J.L. and Hasinoff, B.B. (1995). Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant doxorubicin cardioprotective agent ICRF-187 (dexrazoxane). Arch. Biochem. Biophys. 317: 121-127.
30. Petrat, F., de Groot, H., and Rauen, U. (2001). Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells. Biochem. J. 356:61-69.
31. Picard, V., Epsztejn, S., Santambrogio, P., Cabantchik, Z.I., and Beaumont, C. (1998). Role of ferritin in the control of the labile iron pool in murine erythroleukemia cells. J. Biol. Chem. 273:15,382-15,386.
32. Hochster, H., Liebes, L., Wadler, S., Oratz, R., Wernz, J.C., Meyers, M., et al. (1992). Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84:1725-1730.
33. Petrat, F., Rauen, U., and de Groot, H. (1999). Determination of the chelatable iron pool of isolated rat hepatocytes by digital fluorescence microscopy using the fluorescent probe, phen green SK. Hepatology 29:1171-1179.
34. van Jaarsveld, H., Potgieter, G.M., Kuyl, J.M., Barnard, H.C., and Barnard, S.P. (1990). The effect of desferal on rat heart mitochondrial function, iron content, and xanthine dehydrogenase/oxidase conversion during ischemia-reperfusion. Clin. Biochem. 23:509-513.
35. Moridani, M.Y. and O'Brien, P.J. (2001). Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers. Biochem. Pharmacol. 62: 1579-1585.